Evidence map›Paper›PMID 31060240›Full record

ArticleCells2019

Onset of Telomere Dysfunction and Fusions in Human Ovarian Carcinoma.

Nazmul Huda, Yan Xu, Alison M Bates, Deborah A Rankin, Nagarajan Kannan, David Gilley

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nazmul HudaDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA. nhuda@iu.edu.ORCID 0000-0002-7788-8621
Yan XuDepartment of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. xu2@iu.edu.
Alison M BatesBiochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. alibates@iu.edu.
Deborah A RankinDepartment of Chemistry and Applied Biological Science, South Dakota School of Mines and Technology, Rapid City, SD 57701, USA. deborah.rankin@mines.sdsmt.edu.
Nagarajan KannanDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. Kannan.Nagarajan@mayo.edu.ORCID 0000-0002-8825-2178
David GilleyDepartment of Chemistry and Applied Biological Science, South Dakota School of Mines and Technology, Rapid City, SD 57701, USA. david.gilley@sdsmt.edu.
Indiana University School of MedicineSouth Dakota School of Mines and Technology · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomere dysfunction has been strongly implicated in the initiation of genomic instability and is suspected to be an early event in the carcinogenesis of human solid tumors. Recent findings have established the presence of telomere fusions in human breast and prostate malignancies; however, the onset of this genomic instability mechanism during progression of other solid cancers is not well understood. Herein, we explored telomere dynamics in patient-derived epithelial ovarian cancers (OC), a malignancy characterized by multiple distinct subtypes, extensive molecular heterogeneity, and widespread genomic instability. We discovered a high frequency of telomere fusions in ovarian tumor tissues; however, limited telomere fusions were detected in normal adjacent tissues or benign ovarian samples. In addition, we found relatively high levels of both telomerase activity and hTERT expression, along with anaphase bridges in tumor tissues, which were notably absent in adjacent normal ovarian tissues and benign lesions. These results suggest that telomere dysfunction may occur early in ovarian carcinogenesis and, importantly, that it may play a critical role in the initiation and progression of the disease. Recognizing telomere dysfunction as a pervasive feature of this heterogeneous malignancy may facilitate the future development of novel diagnostic tools and improved methods of disease monitoring and treatment.

Indexed as

AdultAgedAged, 80 and overAnaphaseFemaleHumansMiddle AgedOvarian NeoplasmsTelomeraseTelomereTelomerasegenomic instabilityovarian carcinomatelomerasetelomeretelomere dysfunction

Identifiers

PMID31060240
PMCPMC6562548
OpenAlexW2942637615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.